Showing 1 - 2 results of 2 for search 'Ko, N.-Y' Skip to content
Open Access
  • Home
  • Collections
    • High Impact Articles
    • Jawi Collection
    • Malay Medicine
    • Forensic
  • Search Options
    • UiTM Open Access
    • Search by UiTM Scopus
    • Advanced Search
    • Search by Category
  • Discovery Service
    • Sources
    • UiTM Journals
    • List UiTM Journal in IR
    • Statistic
  • About
    • Open Access
    • Creative Commons Licenses
    • COKI | Malaysia Open Access
    • User Guide
    • Contact Us
    • Search Tips
    • FAQs
Advanced
  • Author
  • Ko, N.-Y
Showing 1 - 2 results of 2 for search 'Ko, N.-Y', query time: 0.11s Refine Results
  1. 1
    Cost-Effectiveness of Juluca (dolutegravir/rilpivirine) for Human Immunodeficiency Virus (HIV-1) Infection Treatment in Virologically Suppressed Adults in Taiwan
    Cost-Effectiveness of Juluca (dolutegravir/rilpivirine) for Human Immunodeficiency Virus (HIV-1) Infection Treatment in Virologically Suppressed Adults in Taiwan
    by Anderson, S.-J, Hsu, C.-Y, Ko, N.-Y, Lopes, S., Ou, H.-T, Yang, C.-T
    Published 2021
    Call Number: Loading...
    Located: Loading...
    View Fulltext in Publisher
    Article
  2. 2
    Physical functioning, frailty and risks of locally-advanced breast cancer among older women
    Physical functioning, frailty and risks of locally-advanced breast cancer among older women
    by Calip, G.S, Chiu, B.C.-H, Coleman, C., Hoskins, K.F, Ko, N.Y, Nabulsi, N.A, Yan, C.H
    Published 2022
    Call Number: Loading...
    Located: Loading...
    View Fulltext in Publisher
    Article
Search Tools: Get RSS Feed — Email this Search

Related Subjects

Adult Anti-HIV Agents Article CD4 lymphocyte count Cost-Benefit Analysis Drug Combinations HIV HIV Infections Heterocyclic Compounds, 3-Ring Human immunodeficiency virus 1 infection Human immunodeficiency virus infection Humans Markov state model Rilpivirine Taiwan abacavir plus dolutegravir plus lamivudine adult anti human immunodeficiency virus agent cardiovascular disease chronic kidney failure clinical outcome cobicistat plus elvitegravir plus emtricitabine plus tenofovir alafenamide cost benefit analysis cost control cost effectiveness analysis cost-effectiveness data base decision tree dolutegravir dolutegravir plus rilpivirine

© 2020 | Services hosted by the Perpustakaan Tun Abdul Razak, | Universiti Teknologi MARA | Disclaimer


Loading...